Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries

Olulanu H. Aina, Jan Marik, Ruiwu Liu, Derick H Lau, Kit Lam

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Using "one-bead one-compound" combinatorial chemistry technology, we generated random peptide libraries containing millions of 90 μm TentaGel beads, each with its own unique amino acid sequence. A cyclic random 8-mer library was screened with CAOV-3 (a human ovarian adenocarcinoma cell line) and beads with a unique ligand that bind to the cell surface receptors were coated by one or more layers of cells. These positive beads were isolated, stripped, and microsequenced. Several peptide motifs were identified from these screenings, some of which were novel and unique, e.g., cDGX4GX6X7c. Structure-activity relationship studies of this peptide revealed that the L-aspartate residue at position 2, the two glycines at positions 3 and 5, and the two D-cysteines at the amino and COOH terminus are critical for activity. In addition, a hydrophobic residue was preferred at position X4, whereas amino acids at positions X6 and X7 were more variable. Binding of this peptide to a number of different cancer cell lines and normal cells was also determined and we observed that peptides with this motif bound preferentially to three other human ovarian cancer cell lines (ES-2, SKOV-3, and OVCAR-3) as well as a human glioblastoma cancer cell line (A172). Structural analysis of the peptides using high-resolution nuclear magnetic resonance spectroscopy revealed strong conformational similarity among all peptides with cX1GX4GX6X7c motif. Blocking study with a panel of anti-integrin antibodies strongly suggests α3 integrin present on these ovarian adenocarcinoma cells is the target receptor for this peptide.

Original languageEnglish (US)
Pages (from-to)806-813
Number of pages8
JournalMolecular Cancer Therapeutics
Volume4
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Ovarian Neoplasms
Peptides
Cell Line
Integrins
Adenocarcinoma
Peptide Library
Peptide Receptors
Cell Surface Receptors
Structure-Activity Relationship
Glioblastoma
Aspartic Acid
Glycine
Libraries
Cysteine
Anti-Idiotypic Antibodies
Amino Acid Sequence
Neoplasms
Magnetic Resonance Spectroscopy
Ligands
Technology

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

@article{294a6944222a4c9ab63f9fbd93a8df52,
title = "Identification of novel targeting peptides for human ovarian cancer cells using {"}one-bead one-compound{"} combinatorial libraries",
abstract = "Using {"}one-bead one-compound{"} combinatorial chemistry technology, we generated random peptide libraries containing millions of 90 μm TentaGel beads, each with its own unique amino acid sequence. A cyclic random 8-mer library was screened with CAOV-3 (a human ovarian adenocarcinoma cell line) and beads with a unique ligand that bind to the cell surface receptors were coated by one or more layers of cells. These positive beads were isolated, stripped, and microsequenced. Several peptide motifs were identified from these screenings, some of which were novel and unique, e.g., cDGX4GX6X7c. Structure-activity relationship studies of this peptide revealed that the L-aspartate residue at position 2, the two glycines at positions 3 and 5, and the two D-cysteines at the amino and COOH terminus are critical for activity. In addition, a hydrophobic residue was preferred at position X4, whereas amino acids at positions X6 and X7 were more variable. Binding of this peptide to a number of different cancer cell lines and normal cells was also determined and we observed that peptides with this motif bound preferentially to three other human ovarian cancer cell lines (ES-2, SKOV-3, and OVCAR-3) as well as a human glioblastoma cancer cell line (A172). Structural analysis of the peptides using high-resolution nuclear magnetic resonance spectroscopy revealed strong conformational similarity among all peptides with cX1GX4GX6X7c motif. Blocking study with a panel of anti-integrin antibodies strongly suggests α3 integrin present on these ovarian adenocarcinoma cells is the target receptor for this peptide.",
author = "Aina, {Olulanu H.} and Jan Marik and Ruiwu Liu and Lau, {Derick H} and Kit Lam",
year = "2005",
month = "5",
doi = "10.1158/1535-7163.MCT-05-0029",
language = "English (US)",
volume = "4",
pages = "806--813",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries

AU - Aina, Olulanu H.

AU - Marik, Jan

AU - Liu, Ruiwu

AU - Lau, Derick H

AU - Lam, Kit

PY - 2005/5

Y1 - 2005/5

N2 - Using "one-bead one-compound" combinatorial chemistry technology, we generated random peptide libraries containing millions of 90 μm TentaGel beads, each with its own unique amino acid sequence. A cyclic random 8-mer library was screened with CAOV-3 (a human ovarian adenocarcinoma cell line) and beads with a unique ligand that bind to the cell surface receptors were coated by one or more layers of cells. These positive beads were isolated, stripped, and microsequenced. Several peptide motifs were identified from these screenings, some of which were novel and unique, e.g., cDGX4GX6X7c. Structure-activity relationship studies of this peptide revealed that the L-aspartate residue at position 2, the two glycines at positions 3 and 5, and the two D-cysteines at the amino and COOH terminus are critical for activity. In addition, a hydrophobic residue was preferred at position X4, whereas amino acids at positions X6 and X7 were more variable. Binding of this peptide to a number of different cancer cell lines and normal cells was also determined and we observed that peptides with this motif bound preferentially to three other human ovarian cancer cell lines (ES-2, SKOV-3, and OVCAR-3) as well as a human glioblastoma cancer cell line (A172). Structural analysis of the peptides using high-resolution nuclear magnetic resonance spectroscopy revealed strong conformational similarity among all peptides with cX1GX4GX6X7c motif. Blocking study with a panel of anti-integrin antibodies strongly suggests α3 integrin present on these ovarian adenocarcinoma cells is the target receptor for this peptide.

AB - Using "one-bead one-compound" combinatorial chemistry technology, we generated random peptide libraries containing millions of 90 μm TentaGel beads, each with its own unique amino acid sequence. A cyclic random 8-mer library was screened with CAOV-3 (a human ovarian adenocarcinoma cell line) and beads with a unique ligand that bind to the cell surface receptors were coated by one or more layers of cells. These positive beads were isolated, stripped, and microsequenced. Several peptide motifs were identified from these screenings, some of which were novel and unique, e.g., cDGX4GX6X7c. Structure-activity relationship studies of this peptide revealed that the L-aspartate residue at position 2, the two glycines at positions 3 and 5, and the two D-cysteines at the amino and COOH terminus are critical for activity. In addition, a hydrophobic residue was preferred at position X4, whereas amino acids at positions X6 and X7 were more variable. Binding of this peptide to a number of different cancer cell lines and normal cells was also determined and we observed that peptides with this motif bound preferentially to three other human ovarian cancer cell lines (ES-2, SKOV-3, and OVCAR-3) as well as a human glioblastoma cancer cell line (A172). Structural analysis of the peptides using high-resolution nuclear magnetic resonance spectroscopy revealed strong conformational similarity among all peptides with cX1GX4GX6X7c motif. Blocking study with a panel of anti-integrin antibodies strongly suggests α3 integrin present on these ovarian adenocarcinoma cells is the target receptor for this peptide.

UR - http://www.scopus.com/inward/record.url?scp=20044381292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044381292&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0029

DO - 10.1158/1535-7163.MCT-05-0029

M3 - Article

VL - 4

SP - 806

EP - 813

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -